|
1
|
Li Y, Lv S, Zeng Y, Chen Z, Xia F, Zhang H, Dan D, Hu C, Tang Y, Yang Q, Ji Y, Lu J, Wang Z. Evaluation of Stability, Inactivation, and Disinfection Effectiveness of Mpox Virus. Viruses 2024; 16:104. [PMID: 38257804 PMCID: PMC10820592 DOI: 10.3390/v16010104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2023] [Revised: 01/08/2024] [Accepted: 01/08/2024] [Indexed: 01/24/2024] Open
Abstract
BACKGROUND Mpox virus (MPXV) infections have increased in many countries since May 2022, increasing demand for diagnostic tests and research on the virus. To ensure personnel safety, appropriate and reliable measures are needed to disinfect and inactivate infectious samples; Methods: We evaluated the stability of infectious MPXV cultures stored at different temperatures and through freeze-thaw cycles. Heat physical treatment (56 °C, 70 °C, 95 °C), chemical treatment (beta-propiolactone (BPL)) and two commercialized disinfectants (Micro-Chem Plus (MCP) and ethanol) were tested against infectious MPXV cultures; Results: The results indicated that MPXV stability increases with lower temperatures. The MPXV titer was stable within three freeze-thaw cycles and only decreased by 1.04 log10 (lg) 50% cell culture infective dose (CCID50) per milliliter (12.44%) after twelve cycles. MPXV could be effectively inactivated at 56 °C for 40 min, 70 °C for 10 min, and 95 °C for 5 min. For BPL inactivation, a 1:1000 volume ratio (BPL:virus) could also effectively inactivate MPXV. A total of 2% or 5% MCP and 75% ethanol treated with MPXV for at least 1 min could reduce >4.25 lg; Conclusions: MPXV shows high stability to temperature and freeze-thaw. Heat and BPL treatments are effective for the inactivation of MPXV, while MCP and ethanol are effective for disinfection, which could help laboratory staff operate the MPXV under safer conditions and improve operational protocols.
Collapse
Affiliation(s)
- Yuwei Li
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
- State Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430200, China
| | - Shiyun Lv
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
- State Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430200, China
| | - Yan Zeng
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
- State Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430200, China
| | - Zhuo Chen
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
- State Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430200, China
| | - Fei Xia
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
- State Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430200, China
| | - Hao Zhang
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
- State Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430200, China
| | - Demiao Dan
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
- State Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430200, China
| | - Chunxia Hu
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
- State Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430200, China
| | - Yi Tang
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
- State Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430200, China
| | - Qiao Yang
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
| | - Yaqi Ji
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
| | - Jia Lu
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
- State Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430200, China
| | - Zejun Wang
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430200, China; (Y.L.); (S.L.); (Y.Z.); (Z.C.); (F.X.); (H.Z.); (D.D.); (C.H.); (Y.T.); (Q.Y.); (Y.J.)
- State Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430200, China
| |
Collapse
|
|
2
|
Zhang Y, Yang R, Yuan G, Li W, Cui Z, Xiao Z, Dong X, Yang H, Liu X, Zhang L, Hou Y, Liu M, Liu S, Hao Y, Zhang Y, Zheng X. Enhancing Inactivated Yellow Fever 17D Vaccine-Induced Immune Responses in Balb/C Mice Using Alum/CpG. Vaccines (Basel) 2023; 11:1744. [PMID: 38140149 PMCID: PMC10747526 DOI: 10.3390/vaccines11121744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2023] [Revised: 11/17/2023] [Accepted: 11/20/2023] [Indexed: 12/24/2023] Open
Abstract
There are some concerns about the safety of live attenuated yellow fever vaccines (YF-live), particularly viscerotropic adverse events, which have a high mortality rate. The cellular production of the vaccine will not cause these adverse effects and has the potential to extend applicability to those who have allergic reactions, immunosuppression, and age. In this study, inactivated yellow fever (YF) was prepared and adsorbed with Alum/CpG. The cellular and humoral immunities were investigated in a mouse model. The results showed that Alum/CpG (20 μg/mL) could significantly increase the binding and neutralizing activities of the antibodies against YF. Moreover, the antibody level at day 28 after one dose was similar to that of the attenuated vaccine, but significantly higher after two doses. At the same time, Alum/CpG significantly increased the levels of IFN-γ and IL-4 cytokines.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Yuntao Zhang
- Beijing Institute of Biological Products Company Limited, Beijing 100170, China; (Y.Z.); (R.Y.); (G.Y.); (W.L.); (Z.C.); (Z.X.); (X.D.); (H.Y.); (X.L.); (L.Z.); (Y.H.); (M.L.); (S.L.); (Y.H.)
| | - Xiaotong Zheng
- Beijing Institute of Biological Products Company Limited, Beijing 100170, China; (Y.Z.); (R.Y.); (G.Y.); (W.L.); (Z.C.); (Z.X.); (X.D.); (H.Y.); (X.L.); (L.Z.); (Y.H.); (M.L.); (S.L.); (Y.H.)
| |
Collapse
|
|
3
|
Hansen CA, Barrett ADT. The Present and Future of Yellow Fever Vaccines. Pharmaceuticals (Basel) 2021; 14:ph14090891. [PMID: 34577591 PMCID: PMC8468696 DOI: 10.3390/ph14090891] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2021] [Revised: 08/26/2021] [Accepted: 08/27/2021] [Indexed: 12/05/2022] Open
Abstract
The disease yellow fever (YF) is prevented by a live-attenuated vaccine, termed 17D, which has been in use since the 1930s. One dose of the vaccine is thought to give lifelong (35+ years) protective immunity, and neutralizing antibodies are the correlate of protection. Despite being a vaccine-preventable disease, YF remains a major public health burden, causing an estimated 109,000 severe infections and 51,000 deaths annually. There are issues of supply and demand for the vaccine, and outbreaks in 2016 and 2018 resulted in fractional dosing of the vaccine to meet demand. The World Health Organization (WHO) has established the “Eliminate Yellow Fever Epidemics” (EYE) initiative to reduce the burden of YF over the next 10 years. As with most vaccines, the WHO has recommendations to assure the quality, safety, and efficacy of the YF vaccine. These require the use of live 17D vaccine only produced in embryonated chicken eggs, and safety evaluated in non-human primates only. Thus, any second-generation vaccines would require modification of WHO recommendations if they were to be used in endemic countries. There are multiple second-generation YF vaccine candidates in various stages of development that must be shown to be non-inferior to the current 17D vaccine in terms of safety and immunogenicity to progress through clinical trials to potential licensing. The historic 17D vaccine continues to shape the global vaccine landscape in its use in the generation of multiple licensed recombinant chimeric live vaccines and vaccine candidates, in which its structural protein genes are replaced with those of other viruses, such as dengue and Japanese encephalitis. There is no doubt that the YF 17D live-attenuated vaccine will continue to play a role in the development of new vaccines for YF, as well as potentially for many other pathogens.
Collapse
Affiliation(s)
- Clairissa A. Hansen
- Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-4036, USA;
| | - Alan D. T. Barrett
- Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-4036, USA;
- Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX 77555-4036, USA
- Correspondence:
| |
Collapse
|